Get the Stockscreener App
231.97
0.65%
1.475
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $231.97, with a volume of 2.78M.
It is up +0.65% in the last 24 hours and up +6.26% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$230.50
Open:
$230
24h Volume:
2.78M
Relative Volume:
0.52
Market Cap:
$409.90B
Revenue:
$58.33B
Net Income/Loss:
$3.73B
P/E Ratio:
110.40
EPS:
2.1013
Net Cash Flow:
$18.24B
1W Performance:
+0.79%
1M Performance:
+6.26%
6M Performance:
+32.53%
1Y Performance:
+19.47%
1-Day Range:
$229.22
$233.81
1-Week Range:
$227.59
$234.68
52-Week Range:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
232.03 | 407.19B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
823.45 | 747.19B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.64 | 459.32B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
129.80 | 251.72B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
85.67 | 214.78B | 63.43B | 16.42B | 14.72B | 6.4861 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
FDA Expands AbbVie's Rinvoq (ABBV) Indication for Colitis and Cr - GuruFocus
FDA Expands AbbVie's (ABBV) RINVOQ Approval for Ulcerative Colit - GuruFocus
AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug - Stocktwits
FDA approves updated indication for AbbVie’s RINVOQ in IBD treatment - Investing.com
Use after 1 approved systemic therapy — AbbVie gets FDA approval to update RINVOQ IBD label allowing pre‑TNF use - Stock Titan
2 Dividend Stocks to Double Up on Right Now - The Globe and Mail
Abbvie to Present New Data At Esmo 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors - MarketScreener
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors - Investing News Network
AbbVie (ABBV) to Present New Antibody-Drug Conjugate Data at ESM - GuruFocus
Atria Wealth Solutions Inc. Reduces Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Envestnet Portfolio Solutions Inc. - MarketBeat
Concord Asset Management LLC VA Purchases 1,691 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Vest Financial LLC - MarketBeat
Griffin Asset Management Inc. Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
M.E. Allison & CO. Inc. Has $466,000 Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by MOKAN Wealth Management Inc. - MarketBeat
AbbVie Inc. $ABBV is Welch Group LLC's 9th Largest Position - MarketBeat
Almanack Investment Partners LLC. Boosts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Pharma companies announce direct-to-consumer sales and price cuts in US - Reuters
The Best Dividend ETF to Invest $1,000 in Right Now - The Motley Fool
Criteria Caixa S.A.U. Sells 47,822 Shares of AbbVie Inc. $ABBV - MarketBeat
Cwm LLC Has $60.03 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV is Advocate Group LLC's 4th Largest Position - MarketBeat
Vanguard Personalized Indexing Management LLC Acquires 37,680 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by OFI Invest Asset Management - MarketBeat
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Buys Shares of 23,920 AbbVie Inc. $ABBV - MarketBeat
Sather Financial Group Inc Purchases New Position in AbbVie Inc. $ABBV - MarketBeat
2,500 Shares in AbbVie Inc. $ABBV Bought by Summa Corp. - MarketBeat
Johnson Investment Counsel Inc. Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
Why Analysts See AbbVie’s Story Shifting After Strategic Wins and Growth Upgrades - Yahoo Finance
AbbVie Inc. $ABBV Holdings Lowered by Natural Investments LLC - MarketBeat
Fifth Third Wealth Advisors LLC Sells 4,542 Shares of AbbVie Inc. $ABBV - MarketBeat
One Degree Advisors Inc Buys New Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Conning Inc. - MarketBeat
Drucker Wealth 3.0 LLC Purchases 2,817 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Eastern Bank - MarketBeat
Forefront Analytics LLC Invests $1.28 Million in AbbVie Inc. $ABBV - MarketBeat
Lmcg Investments LLC Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Strong Tower Advisory Services Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Lowered to Hold Rating by Wall Street Zen - MarketBeat
AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing - Bioprocess Online
Goldman Sachs Adjusts AbbVie Price Target to $218 From $217, Maintains Neutral Rating - MarketScreener
Why AbbVie Inc. is moving todayJuly 2025 Price Swings & Consistent Growth Equity Picks - newser.com
Piper Sandler raises Abbvie stock price target to $284 on strong portfolio - Investing.com Canada
Piper Sandler Raises Price Target for AbbVie (ABBV) to $284, Mai - GuruFocus
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - Yahoo Finance
Blue Trust Inc. Trims Position in AbbVie Inc. $ABBV - MarketBeat
Cyndeo Wealth Partners LLC Grows Stake in AbbVie Inc. $ABBV - MarketBeat
Commerzbank Aktiengesellschaft FI Has $24.07 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Cardano Risk Management B.V. Grows Holdings in AbbVie Inc. $ABBV - MarketBeat
McKinley Carter Wealth Services Inc. Raises Stake in AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):